reason report
bottom line revenue procedur outlook
consist pre-announce link full
oper result impress revenue y/i revenue
growth op margin out-performance
ep beat also continu believ management procedur outlook
issu conserv leav room upsid
revis rev/ep forecast main new updat call
includ guidanc op-ex growth bracket us/th street stock
base compens sbc us int incom us/street
tax us/street net lead slight reduct
ep -- -albeit mostli due non-oper tax/
int incom item consid benign revenue
increas howev near-term ep estim move lower
reflect updat guidanc stock could give back
recent run-up post revenue pre-announce part come
strong oper rel unphas fulli
expect conserv outlook begin year see
growth momentum big estimate upsid potenti sustain out-
year new product cycl sp ion stapler continu
matur compani drive increas penetration/ accept
grow set int market new us gen surgeri procedur
dcf-base pt goe vs reflect increas
out-year revenue forecast assumpt today invest
continu yield increas margin payoff futur
revenue estim increas ep move lower
reflect midpoint guidanc updat higher tax rate
lower int incom off-set higher revenue forecast assum
higher unit placement procedur growth midpoint
guidanc rang partial off-set lower instrument accessori ina
revenue per procedur due mix -- -per management commentari call
street recal pre-announce revenue y/i
beat consensu time pre-announce
revenue y/i compar consensu
unit compar consensu instrument accessori
 revenue y/i compar consensu
servic revenue y/i basic in-lin
asp significantli ahead think ww y/
procedur growth trend impress y/i clip beat
consensu full detail show gm adj ebita margin
beat vs vs
medic suppli devic
dcf wgtd average cost
net debt total capit
price-to-earnings lt ep growth
year price history/av daili volume mil
compani inform svb leerink llc research
revenu mm ep ex item stock expens defer revenu amort
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
respect adj ep consensu svbl
item tax/int incom gm expect captur
consensu due higher sale newer product
infrastructur invest opex growth expect increas
y/i bracket us/consensu howev lower-than-
expect incom guid svbl higher
tax rate svbl net lead
slight reduct ep part model adj ep
vs prior vs prior
reflect y/i growth respect believ management
guidanc leav room upsid revis ep forecast
ww procedur growth outlook reiter issu
start year management tend take conserv approach guidanc
onset year upper end rang highli achiev
beatabl exceed upper end origin
issu procedur guidanc rang
compani exceed upper end initi guidanc rang
respect expect similar approach
guidanc year high confid head
plu cholecystectomi potenti acceler momentum
japan china note china system among
product system util standpoint placements/
new hospit bode well lt oppti china alreadi
start see growth re-acceler china procedur growth acceler
came overal procedur growth level
trend acceler one throughout
overal ou growth average qtr
revenu includ ina revenu per procedur could
moder benign procedur grow faster procedur use
advanc instrument mix shift -- model modest declin
 oper leas altern financ agreement
increas proport system placement overtim -- model
ww oper leas vs caus system
declin trade-in instal base trend
downward -- model lower trade-in consist
prior commentari respect anticip competit management
continu expect intensifi start europ estim
time like time-frame us may elong capit
sell cycl hospit trial/dilig altern solut
rate share outperform ultim believ key valu driver
place stock work intermediate-to-longer-term acceler
procedur growth new product cycl momentum continu uniqu robot
colorect bariatr thorac head neck other acceler growth procedur
adopt intern dvp da vinci prostatectomi europ japan addtl procedur
reimburs china new quota new product cycl xi sp ion help
sustain above-averag top- bottom-lin double-digit growth system advanc
continu open increment surgery/revenu sourc time surpris
management want dial reinvest time two back-to-back new product cycl
sp flex cathet robot line sight multipl lt develop opportun
 expans china india informatics/ai surgeri initi expect stepped-
invest ultim enhanc market leadership posit expand surgic
robot categori potenti increas payoff out-year also continu
believ sustain uniqu large-cap med-tech mid-teen revenue growth least profil
complement mid-teen better ep growth compound-annual-growth-rate
valuat base dcf analysi yield pt vs prior
discount rate calcul use capm model current trade price-to-earnings
ex-cash basi incl cash ex-cash incl cash vs broader
market cap med-tech average incl ew
pt impli appli adj ep less int incom
cash believ isrg premium group sustain given above-averag
top- bottom-lin growth compound-annual-growth-rate potenti vs peer amid multipl new product cycl
help drive increas penetr still-larg under-penetrated long-term robot surgeri
risk valuat includ high volatil wide-trad rang stock
compani relianc singl product robot potenti chang wors hospit
capit spend environ continu debat around cost/benefit come
adopt robot procedur current project valuat could risk
gyn/uro trend slow greater degre model newer gener surgeri robot
procedur slower expect adopt forecast anticipated-to-launch
nexgen sp platform delay fail gain traction launch compani cant
achiev revenu contribut model flexibl cathet robot program
key risk includ ou growth slower anticip -- -either due delay
newer robot entrant mdt/jnj beyond come onto scene result
competit trial potenti caus hospit purchas cycl elong given
robot solut evalu sg invest combat competit
develop new market lead greater opex spend -- -potenti limit near-term earn
power -- -v weve model
dollar million except per share data
good sold ex-amort/sbc/def cogs
disc op debt ext /recap net tax
pre-split dilut averag share million
post-split dilut averag share million
compani report svb leerink llc estim
note pre-announce preliminari revenu metric provid
dollar million except per share data
total
revenu mix sale
compani report svb leerink llc estim
note pre-announce preliminari revenu metric provid
